Phase III data support Epix Medical's MRA (magnetic resonance angiography) contrast agent
This article was originally published in Clinica
Executive Summary
Epix Medical's contrast agent for enhancing magnetic resonance angiography (MRA) has produced positive preliminary results in a phase III clinical trial of the product.